Neuron23 is developing NEU-411, a potent, selective, brain-penetrant oral inhibitor of the LRRK2 kinase pathway intended to treat LRRK2-driven Parkinson’s disease. The company is running the global Phase 2 NEULARK clinical trial that prospectively identifies patients with LRRK2-driven disease and randomized them to receive NEU-411 or placebo for a 52-week treatment period. NEULARK is among the first Parkinson’s trials to apply a precision medicine approach and uses Roche’s smartphone-based digital biomarker software to frequently monitor motor and non-motor symptoms. Neuron23 has identified single-nucleotide polymorphisms predicted to drive LRRK2 overactivity in up to 30% of people with idiopathic Parkinson’s disease and includes people with LRRK2 gene mutations in its target population. The company is expanding NEULARK into Israel with clinical sites in Tel Aviv, Jerusalem, and Haifa and recently screened its first patient there. Neuron23 has partnered with Sano Genetics to streamline referrals and offer saliva test kits to identify potential trial participants. The $2.5 million grant from The Michael J. Fox Foundation will support site activation and patient screening for the Israeli expansion.

Total raised

$313M

Funding rounds

5

Latest round

Grant

Latest activity

Jun 2026